Continuous Theta Burst Stimulation for Generalized Anxiety Disorder (cTBS for GAD)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, rater-blinded trial compares two cTBS targets in adults with generalized anxiety disorder to see if symptoms improve. Participants may be medication-free or on stable psychotropic meds per protocol. The main outcome is change in anxiety severity using the HAM-A from baseline to end of treatment, with secondary measures including treatment response, quality of life, sleep, cognitive function, safety, and neurophysiological data (resting EEG and TMS-EEG). The study aims to clarify whether targeting the right PPC or right DLPFC with cTBS is safe and more effective for GAD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 to 65 years.
* Right-handed.
* Diagnosis of generalized anxiety disorder (GAD) according to ICD-10 criteria (F41.1), confirmed by a psychiatrist.
* GAD must be the primary diagnosis and the main reason for treatment at the time of enrollment. Current or past comorbid major depressive disorder will be identified and recorded.
* Hamilton Anxiety Rating Scale (HAM-A) total score \>18 at screening/baseline.
* Able and willing to provide written informed consent and comply with essential study procedures.
* Participants may be psychotropic-medication naïve or may be receiving psychotropic medication. Participants currently receiving psychotropic medication must have maintained the same medication(s) and dose(s) for at least 2 weeks before randomization; for fluoxetine, the required stable period is at least 4 weeks.

Exclusion Criteria:

* Intracranial or head/neck metallic foreign bodies or implants that constitute a contraindication to TMS or MRI.
* Implanted electronic devices such as a cardiac pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator.
* Untreated or clinically unstable thyroid dysfunction based on abnormal TSH and/or free T4 levels.
* Clinically significant intracranial structural abnormalities that may affect TMS safety, neuropsychiatric presentation, or study neurophysiological measures.
* History of epilepsy or seizures, except febrile seizures in childhood.
* Bipolar disorder.
* Other major psychiatric disorders, including schizophrenia, delusional disorder, or eating disorders.
* Acute suicide risk, including clear suicidal ideation or behavior.
* Alcohol or substance abuse or dependence within the previous 6 months.
* A medical condition associated with a high seizure risk or a history of cranial surgery.
* Current use of medication judged by the screening physician to substantially increase seizure risk, or rapid reduction/discontinuation of benzodiazepines, antiseizure medications, or other centrally acting medications associated with withdrawal or increased seizure risk.
* Serum vitamin D level \<20 ng/mL that has not been adequately corrected.
* Elevated C-reactive protein associated with clinically significant acute infection or acute inflammatory illness that, in the investigator's judgment, may affect participant safety or study outcome assessment.
* Pregnant or breastfeeding.
* Unable to understand or complete essential study procedures. Participants with potentially reversible temporary exclusion conditions may be rescreened once the condition has been adequately corrected or clinically stabilized.

Where it's running

• Military Hospital 175
  Ho Chi Minh City, Vietnam Recruiting

Study contacts

• Study coordinator: Dang Minh Ly, MD
• Email: drminhdang@outlook.com
• Phone: +84359999741

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjunctive JNJ-99245354 for Generalized Anxiety Disorder (GAD)

  This study tests whether adding JNJ-99245354 to existing GAD treatment helps reduce anxiety more than a placebo for adults with GAD who didn’t get adequate benefit from previous treatments.

  Recruiting at 4 sites Phase 3 Intra-Cellular Therapies, Inc. · Temecula, California and 3 other locations · NCT07856420

• Testing ITI-1284 for Generalized Anxiety Disorder (GAD)

  This phase 3 trial tests whether ITI-1284 is safe and tolerable when taken alone or with other medicines by adults with generalized anxiety disorder who haven’t responded to prior treatment.

  Recruiting at 3 sites Phase 3 Intra-Cellular Therapies, Inc. · Los Angeles, California and 2 other locations · NCT07807865

• Long-term safety and tolerability of SEP-363856 in adults with generalized anxiety disorder

  In adults with generalized anxiety disorder, this Phase 3 open-label extension tests whether continuing SEP-363856 at 50 mg or 75 mg daily for 26 weeks is safe, tolerable, and possibly helpful.

  Recruiting at 2 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Jacksonville, Florida and 1 other locations · NCT07786454

• Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety

  This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.

  Recruiting Ohio State University · Columbus, Ohio · NCT07774481

• Fixed-dose SEP-363856 vs placebo for adults with generalized anxiety disorder

  This trial tests whether a fixed 75 mg/day dose of SEP-363856 helps adults with generalized anxiety disorder more than placebo over 8 weeks.

  Recruiting at 11 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Redlands, California and 10 other locations · NCT07767903

• Fixed-dose SEP-363856 for Generalized Anxiety Disorder

  A large, global study will test whether daily doses of SEP-363856 (50 mg or 75 mg) help adults with generalized anxiety disorder more than a placebo over 8 weeks.

  Recruiting at 17 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Tucson, Arizona and 16 other locations · NCT07759128

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.